Ovarian cancer is one of the most dismal types of gynecological cancer. Pathobiology is understudied and poorly understood due to the absence of adequate models to study the illness. Organoids are defined as self-developing 3D structures in vitro reconstructions of tissues, which constitute powerful tools to model and study human diseases. These organoid models retain and reproduce the primary ovarian cancer attributes, including the key architectural, cellular, and genetic heterogeneity of the primary tumor, as well as the various subtypes, not limited to the high-grade serous, endometrioid, clear cell, and mucinous carcinomas. Cultured in defined, extracellular matrix-rich conditions, these organoids expand while preserving the tumor's original mutational landscape, gene expression profiles, and distinct tumor microenvironmental features, offering a superior alternative to traditional 2D cultures.
The organoid model for ovarian cancer can offer a sustainable model for ovarian cancer research. This model permits the culturing of various subtypes of ovarian cancers, the assessment of their genomic profiles, and the screening of potential pharmacological agents. Additionally, in cancer individuals, this model serves to evaluate the chemosensitivity and radiosensitivity of tumors and to enhance the therapeutic response of the individuals.
Recapitulation of Tumor Heterogeneity
Capable of mirroring the inter- and intra-tumoral genetic and cellular diversity of ovarian cancer, providing a more accurate platform for studying tumor biology and evolution.
Advanced Drug Screening and Development
For novel therapeutics, including chemotherapy, targeted agents, and immunotherapies, organoids offer a high-throughput, physiologically relevant model to assess efficacy and mechanisms of action of drugs.
Modeling Tumor Microenvironment (TME)
Can be co-cultured with various stromal and immune cells to study complex tumor-stroma interactions, immune cell infiltration, and their impact on therapy response and resistance.
Investigation of Drug Resistance Mechanisms
It is possible to use this model to elucidate intrinsic and acquired resistance pathways, and the discovery of biomarkers and testing of combination approaches to overcome resistance.
Utilizing our broad knowledge of 3D model development and a synergistic approach, Alfa Cytology offers comprehensive ovarian cancer organoid development services. Our commitment allows us to create organoid models that possess a high level of fidelity and validation, as well as a comprehensive organoid model-based solution that expedites your research and drug development processes in oncology.
Alfa Cytology provides versatile development services for a broad spectrum of ovarian cancer organoid models, ensuring the right model system for your specific research needs.
In addition to developing models, we also provide a range of advanced research services that use ovarian cancer organoid models. Our research services using organoid models assist in the study of tumor biology, signaling pathways, and the mechanisms of progression. Furthermore, our organoid model-based preclinical research services provide a robust platform for compound screening, efficacy testing, biomarker discovery, and toxicity assessment, effectively bridging the gap between traditional in vitro assays and in vivo studies.
Using established PDX models of ovarian cancer, solid tumor tissues or malignant ascites were processed for organoid generation. Tumor samples were minced into fragments and then enzymatically digested to achieve a cell suspension. For the initiation of organoid culture, a defined number of cancer cells were incorporated into a proprietary extracellular matrix and plated as individual domes, thereafter overlaid with a specialized medium containing essential growth factors and small molecule inhibitors. The generated PDXOs were subsequently subjected to drug response testing, where they exhibited specific therapy sensitivities. These findings confirmed the platform's effectiveness as a reliable and physiologically relevant model system for innovative drug screening and the development of personalized therapeutic strategies.
Fig.1 Establishment of an ovarian cancer PDXO model.
Providing a comprehensive and integrated suite of services for ovarian cancer organoid development and subsequent research applications, Alfa Cytology is positioned as a dedicated partner in advancing ovarian cancer research. Our models and services are designed to deliver biologically relevant, trustworthy data to empower your scientific discoveries and therapeutic innovations. To discuss your specific project requirements and how our expertise can be leveraged, please contact our scientific team to initiate a collaboration.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.
